FDA Greenlights Relacorilant

Physician associates (PAs) in oncology are transitioning from task-oriented roles to “patient experience architects” who are essential for maintaining continuity of care amid oncologist shortages. According to Hardik Thakkar, MSPAS, PA-C, the generalist training of PAs allows them to manage a patient’s comorbid conditions alongside their cancer treatment, significantly reducing care fragmentation.

For oncology nurses caring for patients with KRAS G12C-mutant metastatic non–small cell lung cancer (NSCLC), new data from the phase 1 KANDLELIT-001 trial (NCT05067283) suggest a shifting treatment landscape.

Data from a phase 1 study (NCT05382559) presented at the 2026 European Lung Cancer Congress (ELCC) and published in The New England Journal of Medicine indicate that setidegrasib, a first-in-class protein degrader, yielded significant antitumor activity with a tolerable safety profile in patients with KRAS G12D-mutant non–small cell lung cancer (NSCLC).1,2 Managing the Toxicity Profile: A Focus on Infusion-Related Reactions To provide a nursing perspective, the primary takeaway from the...